Magnesium Sulfate for Acute Migraine: Not Recommended as First-Line Therapy
Magnesium sulfate is not included in the most recent 2025 American College of Physicians guidelines for acute migraine treatment and should not be used as a primary therapy for acute migraine attacks in the emergency department or outpatient settings. 1
Current Evidence-Based Treatment Algorithm
The 2025 ACP guidelines provide a clear hierarchical approach for acute migraine management:
First-Line Treatment
- Mild to moderate migraine: Start with NSAIDs (ibuprofen, naproxen, diclofenac) or acetaminophen 1
- Moderate to severe migraine: Use combination therapy with a triptan PLUS an NSAID (or acetaminophen if NSAIDs contraindicated) 1
Second-Line Options
If first-line therapy fails, consider:
- CGRP antagonists (gepants: rimegepant, ubrogepant, zavegepant)
- Dihydroergotamine
- Lasmiditan (if all other options have failed) 1
What NOT to Use
- Opioids and butalbital are explicitly contraindicated for acute migraine 1
Why Magnesium Sulfate Is Not Recommended
Conflicting Research Evidence
The evidence for IV magnesium sulfate in acute migraine is highly inconsistent:
Negative findings: A 2001 randomized trial showed that adding 2g IV magnesium sulfate to metoclopramide actually worsened outcomes compared to metoclopramide alone, with a number needed to harm of 4 patients 2. A 2005 placebo-controlled trial found magnesium had analgesic effects similar to placebo 3.
Mixed results: While some studies (4, 5) showed benefit with 1-2g IV magnesium sulfate, these were lower-quality trials with significant methodological limitations.
Subgroup considerations: One 2002 study suggested possible benefit specifically for migraine with aura, but not for migraine without aura 6.
Guideline Exclusion
Most importantly, the 2025 American Headache Society emergency department guideline update 7 and the 2025 ACP guidelines 1 do not include magnesium sulfate among recommended parenteral therapies. This omission is telling—if the evidence were compelling, it would be included.
Oral Magnesium for Prevention (Different Context)
The 2024 VA/DoD guidelines 8 suggest oral magnesium for migraine prevention (not acute treatment), which is an entirely different clinical scenario than treating an active attack. This should not be confused with IV magnesium for acute episodes.
FDA-Approved Indications
The FDA labeling for IV magnesium sulfate 9 lists approved uses as:
- Magnesium deficiency
- Pre-eclampsia/eclampsia
- Hyperalimentation
Acute migraine is NOT an FDA-approved indication. The label provides no dosing guidance for migraine treatment.
Clinical Pitfalls to Avoid
- Do not use magnesium sulfate as first-line acute migraine therapy when evidence-based options (NSAIDs, triptans, combination therapy) are available
- Do not confuse oral magnesium for prevention with IV magnesium for acute treatment—these are separate clinical questions with different evidence bases
- Monitor for adverse effects if magnesium is used off-label: flushing, hypotension, respiratory depression (especially with renal impairment) 9
- Avoid in renal insufficiency: Maximum 20g/48 hours with frequent serum monitoring 9
- Do not exceed 150 mg/minute IV infusion rate 9
When Magnesium Might Be Considered
If you encounter a patient who has failed all guideline-recommended therapies and you're considering off-label magnesium:
- Dose: 1-2g IV over 10-15 minutes (based on research trials 4, 5, 6)
- Dilution: Must dilute to ≤20% concentration 9
- Monitoring: Check patellar reflexes, respiratory rate (≥16/min), urine output (≥100 mL/4 hours) 9
- Consider preferentially for migraine with aura based on limited evidence 6
However, before resorting to magnesium, ensure the patient has tried appropriate doses of NSAIDs, triptans, combination therapy, gepants, and dihydroergotamine as outlined in current guidelines 1.